Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial

Table 5 Detailed results of EQ-5D analysis based on a mixed linear model

Effect	Group	Month	Estimate	Standard error	p -value
Intercept			0.3030	0.06016	<.0001
Baseline			0.4947	0.04474	<.0001
Group	Taxane		0.0328	0.07435	0.6591
	S-1		reference	.	.
Visit		3	0.1211	0.04914	0.0139
		6	0.0964	0.04925	0.0505
		12	0.1044	0.04935	0.0345
		18	0.1117	0.04956	0.0243
		24	0.0803	0.04975	0.1067
		30	0.0491	0.05033	0.3297
		36	0.0615	0.05138	0.2317
		42	0.0428	0.05324	0.4219
		48	−0.0014	0.05494	0.9793
		54	−0.0036	0.05813	0.9504
		60	reference	.	.
Group*visit	Taxane	3	−0.0671	0.07489	0.3701
		6	−0.0600	0.07500	0.4238
		12	−0.0831	0.07527	0.2699
		18	−0.0697	0.07578	0.3579
		24	−0.0553	0.07598	0.4665
		30	−0.0228	0.07681	0.7665
		36	−0.0526	0.07774	0.4991
		42	−0.0594	0.08048	0.4603
		48	−0.0005	0.08314	0.9951
		54	0.0294	0.08627	0.7334
		60	reference	.	.

ISSN: 1471-2407